In recent decades, there has been significant progress in the available strategies for the conservative management of CKD, and the selection and appropriate use of these strategies—including RAAS inhibitors, SGLT2 inhibitors, mineralocorticoid receptor antagonists, and GLP-1 receptor agonists—may influence and potentially modify the course of the disease. This evidence concerns the gene NR3C2 and chronic kidney disease.